| | Presentation | Media | Date |
| Poster from Ctad 2024 - Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease
|
| |
October 29, 2024
|
| CEO, Martin Jönsson to presented at Redeye’s Neurology Day, Presentation about AlzeCure, our Alzheimer and pain platforms, projects, etc.
| |
|
October 23, 2024
|
| ACD440 – A novel non-opioid analgesic – From AlzeCures live-event.
| |
|
October 23, 2024
|
| ACD440 – A novel non-opioid analgesic, with Dr. Rolf Karlsten - AlzeCure´s live event.
| |
|
October 23, 2024
|
| ACD440 – A novel non-opioid analgesic, with Märta Segerdahl, CMO and project manager - AlzeCure´s live event.
| |
|
October 23, 2024
|
| Presentation about AlzeCure by CEO Martin Jönsson, presented at LSX Nordic Congress
| |
|
October 8, 2024
|
| Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the ACD856 poster on an anti-inflammatory effect to be presented at CTAD, October 1, 2024 (Swedish)
| |
|
October 1, 2024
|
| AlzeCures CEO, Martin Jönsson at Finwire (Swedish )
| |
|
August 27, 2024
|
| Watch the latest interview at Redeye with our CEO, Martin Jönsson (Swedish)
| |
|
August 20, 2024
|
| Alzecure’s pain project TrkA-NAM presented at the pain conference IASP, Augusti 5-9 2024 – Pharmalogical Effects of ACD137, a Potent and Selective Negative Allosteric Modulator of TrkA
|
| |
August 7, 2024
|
| CEO Martin Jönsson presents at Redeye Investor forum (Swedish)
| |
|
May 16, 2024
|
| Interview at Redeye with CEO, Martin Jönsson (Swedish)
| |
|
May 6, 2024
|
| SITDOWN at Finwire - AlzeCures CEO, Martin Jönsson about the rights issue (Swedish)
| |
|
May 2, 2024
|
| Interview at Finwire with Johan Sandin, CSO (Swedish)
| |
|
May 2, 2024
|
| Rights issue presentation with CEO Martin Jönsson (Swedish)
| |
|
May 2, 2024
|
| AlzeCure's CEO Martin Jönsson at Redeye (Swedish)
| |
|
April 11, 2024
|
| CEO Martin Jönsson presenting at Finwire (Swedish)
| |
|
April 10, 2024
|
| AlzeCure's CEO Martin Jönsson at Redeye's event on Alzheimer's (Swedish)
| |
|
March 21, 2024
|
| AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference, AD/PD 2024
|
|
|
March 7, 2024
|
| Expert Event - Advances in the treatment of Alzheimer’s disease – Small molecule Gamma-Secretase Modulators (GSMs) as promising disease-modifying treatments together
|
|
|
February 19, 2024
|
| Alzheimer’s disease and the amyloid hypothesis – Professor Henrik Zetterberg, MD, PhD, Gothenburg University & University College London, AlzeCure Pharma expert event
|
|
|
February 19, 2024
|
| Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure; AlzeCure Pharma expert event with Johan Sandin, PhD, CSO, AlzeCure
|
|
|
February 19, 2024
|
| Welcome address, agenda & company overview, – Martin Jönsson, CEO, AlzeCure; AlzeCure Pharma expert event - Alzheimer’s around highly current gamma-secretase modulators
|
|
|
February 19, 2024
|
| AlzeCure at Nordic American Healthcare Conference, December 6-7, 2023
|
| |
December 6, 2023
|
| AlzeCure at Redeye Life Science Day 2023 on November 23, 2023
| |
|
November 23, 2023
|
| NeuroRestore ACD856, a Trk-PAM in clinical development for Alzheimer’s disease shows neuroprotective and neurorestorative effects_CTAD 2023
|
| |
October 25, 2023
|
| Clinical results from phase II study with ACD440 in patients with peripheral neuropathic pain. Scientific presentation at the Svenskt Smärtforum conference Oct 12- 13, 2023.
|
| |
October 12, 2023
|
| AlzeCure at Redeye Neurology Theme Event CEO Martin Jönsson presented and answered questions about the latest developments and the company’s plans going forward.
|
|
|
October 11, 2023
|
| Article from Life Science Sweden – DUAL ACTION AGAINST ALZHEIMER’S IN ALZSTATIN
|
| |
October 2, 2023
|
| AlzeCure ACD440 TRPV1 antagonist Ph 2 data, EFIC 2023
|
| |
September 20, 2023
|
| AlzeCure Pharma present at Finwire
| |
|
September 5, 2023
|
| AlzeCure Pharma present at Finwire – CMO Märta Segerdahl
| |
|
September 5, 2023
|
| AlzeCure Pharma present at Finwire – CSO Johan Sandin
| |
|
September 5, 2023
|
| AlzeCure Pharma’s CEO Martin Jönsson – Infocus interview at Redeye Growth Day on June 1th , 2023
| |
|
June 1, 2023
|
| AlzeCure presents at Redeye Growth Day on June 1st , 2023
| |
|
June 1, 2023
|
| Alzstatin – A preventive treatment against Alzheimer’s – Background & Evolution with Johan Sandin
|
|
|
May 17, 2023
|
| Presentation of the development of AlzeCure’s Alzheimer project Alzstatin and NeuroRestore
| |
|
May 17, 2023
|
| Alzheimer’s disease; Challenges & Opportunities with Professor Bengt Winblad Karolinska Institutet
|
|
|
May 17, 2023
|
| NeuroRestore: Background & data supporting disease modifying effects with Pontus Forsell
|
|
|
May 17, 2023
|
| AlzeCure Pharma – Capital Market Day May 17th, 2023
|
|
|
May 17, 2023
|
| Interview at Finwire with CEO Martin Jönsson
| |
|
May 9, 2023
|
| CEO Martin Jönsson at Redeye (Swedish)
| |
|
April 12, 2023
|
| Effects on neuroprotection and neuro plasticity by the clinical compound ACD856, a novel positive modulator of Trk-receptors from the NeuroRestore® platform; AD/PD 2023, March 28 – April 1, 2023
|
|
|
March 28, 2023
|
| In vitro and in vivo profile of AC-0027875 (Alzstatin ACD680), a novel gamma-secretase modulator for the prevention and treatment of Alzheimer’s disease; AD/PD 2023, March 28 – April 1, 2023
|
|
|
March 28, 2023
|
| Sitdown at Finwire with CEO Martin Jönsson
| |
|
March 1, 2023
|
| Watch the interview at Redeye with CEO Martin Jönsson and Märta Segerdahl MD, PhD. Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440. (Swedish)
| |
|
January 31, 2023
|
| CEO Martin Jönsson’s interview with Redeye, the outcome of the issue and milestones in 2023, 9 January (Swedish)
| |
|
January 9, 2023
|
| Erik Penser – Interview with CSO Johan Sandin about AlzeCure’s projects.
| |
|
December 13, 2022
|
| Interview at Finwire news with CEO Martin Jönsson (The presentation will be held in Swedish).
| |
|
December 12, 2022
|
| Erik Penser – Interview with Martin Jönsson about the ongoing Rights Issue.
| |
|
December 6, 2022
|
| Rights Issue presentation with CEO Martin Jönsson at Erik Penser Bank.
|
|
|
December 6, 2022
|
| CEO Martin Jönsson presents AlzeCure at BioStock.
| |
|
December 5, 2022
|
| AlzeCure’s CEO Martin Jönsson presents at BioStock in connection with a new share issue, December 5, 2022.
| |
|
December 5, 2022
|
| Quantitative EEG results from a multiple ascending dose study. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
|
|
November 30, 2022
|
| AC-0027875, a novel gamma-secretase modulator. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
|
|
November 30, 2022
|
| Preclinical characterization of ACD856. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
|
|
November 30, 2022
|
| CEO Martin Jönsson interviewed at Redeye Life Sciences Day on the company’s positive development & plans, as well as about the proposed rights issue in December and the positive progress in the Alzheimer’s market, and what this means for AlzeCure.
| |
|
November 24, 2022
|
| Martin Jönsson presented at Life Science Investor Conference the company’s successes and ongoing projects, as well as the company’s new share issue.
| |
|
November 23, 2022
|
| CEO Martin Jönsson presents AlzeCure’s progress and ongoing projects, as well as the company’s proposed share issue. (English)
| |
|
November 17, 2022
|
| Aktiespararna’s event with AlzeCure on November 16, 2022 – Martin Jönsson, AlzeCure’s CEO, presented the company’s progress and ongoing projects, as well as the company’s planned share issue. The presentation was held in Swedish.
| |
|
November 16, 2022
|
| CEO Martin Jönsson presented an update on our Pain management projects at Redeye Theme: Neurology on October 12.
| |
|
October 12, 2022
|
| CEO Martin Jönsson presented the company’s latest developments at Redeye Theme: Neurology on October 12, 2022.
| |
|
October 12, 2022
|
| The Trk-PAM ACD856 improves mitochondrial function and increases BDNF levels in primary cortical neurons; Scientific presentation at the ISMND Conference, Athens, October 10-12, 2022.
|
| |
October 11, 2022
|
| Analgesic and Anti-inflammatory Effects of Small Molecule Negative Allosteric Modulators of TrkA; Scientific presentation at the IASP Conference, Toronto, September 19-23, 2022.
|
| |
September 22, 2022
|
| Martin talks about the latest developments for AlzeCure including the phase 2 study with ACD 440 against neuropathic pain, the new positive clinical results with NeuroRestore ACD 856, our new patent and the new results with the pain project TrkA-NAM. (Swedish).
| |
|
September 12, 2022
|
| Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the latest clinical progress (Swedish).
| |
|
September 1, 2022
|
| Results From a Multiple Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors AAIC July – Aug 2022.
|
|
|
July 31, 2022
|
| Watch the interview with Aktiespararna at Finwire with AlzeCure’s CEO Martin Jönsson. (Swedish).
| |
|
July 1, 2022
|
| AlzeCure – Interview at Redeye with CEO Martin Jönsson about the phase II study with ACD440. (Swedish).
| |
|
June 23, 2022
|
| AlzeCure at Redeye Growth Day.
| |
|
June 2, 2022
|
| CEO Martin Jönsson Presenting at Redeye Growth Day.
| |
|
May 23, 2022
|
| The use of PathHunter cell lines to discover modulators of Trk-receptors. From HTS to phase 1; Scientific presentation at the ELRIG Conference, Gothenburg, May 10-12, 2022.
|
| |
May 10, 2022
|
| AlzeCure – Alzheimer event at Redeye (Swedish).
| |
|
May 3, 2022
|
| Identification of a positive modulator of neurotrophin recptors with memory-enhancing effects and improved mitochondrial function; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research.
|
| |
April 21, 2022
|
| Preliminary Results From a Single Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm,
|
| |
April 21, 2022
|
| Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm.
|
| |
April 21, 2022
|
| A positive modulator of neurotrophin receptors improves cognition and mitochondrial function; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022.
| |
|
March 17, 2022
|
| NeuroRestore – Preliminary results from a Single Ascending Dose study in healthy volunteers of ACD856, a positive modulator of Neurotrophin Trk-receptors; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022
|
|
|
March 15, 2022
|
| Watch the Analysisguide’s interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the future (in Swedish).
| |
|
March 14, 2022
|
| CEO Martin Jönsson is interview by BioStock on the company’s latest developments, including the ongoing rights issue.
| |
|
March 14, 2022
|
| CSO Johan Sandin explains the science behind AlzeCure’s project portfolio and what distinguishes it from other pharma companies (Swedish).
| |
|
March 14, 2022
|
| See CEO Martin Jönsson and CSO Johan Sandin, present upcoming events in the company and the ongoing issue (Swedish).
| |
|
March 11, 2022
|
| Watch the interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the ongoing issue (Swedish).
| |
|
March 9, 2022
|
| AlzeCure – New presentation at Penser (Swedish).
| |
|
February 24, 2022
|
| Latest newsflow (Swedish).
| |
|
February 3, 2022
|
| CEO Martin Jönsson presents at Aktiespararna (Swedish).
| |
|
January 31, 2022
|
| Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease, Scientific presentation at 11th Pharmaceutical Profiling meeting, January 27, 2022.
|
| |
January 27, 2022
|
| Alzstatin – Development of novel ?-secretase modulators for the treatment of Alzheimer’s disease.
|
| |
January 27, 2022
|
| Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease (Text only).
|
| |
January 27, 2022
|
| AlzeCure Pharma – Kapitalmarknadsdag.
| |
|
January 18, 2022
|
| AlzeCure medverkar på Erik Penser Banks temadag Life Science december 2, 2021 (Swedish)
|
|
|
December 2, 2021
|
| Follow us – Stay updated
| |
|
November 22, 2021
|
| AlzeCure Pharma – Redeye Life Science Day
| |
|
November 11, 2021
|
| AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans.
| |
|
October 22, 2021
|
| Alzecure presents at Healthcare Innovation Summit
|
|
|
October 7, 2021
|
| Characterization of positive allosteric modulators of TrkB for the treatment of depression
|
| |
October 2, 2021
|
| Alzecure Pharma – Naventus Life Science Summit
|
|
|
September 29, 2021
|
| Aktiespararna interview CEO Martin Jönsson – latest quarterly report and future prospects. (Swedish)
| |
|
September 20, 2021
|
| AlzeCure Pharma – Aktiedagen Stockholm. (Swedish)
| |
|
September 7, 2021
|
| Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer
|
|
|
September 1, 2021
|
| NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research
|
|
|
September 1, 2021
|
| Company Overview & Vision by Martin Jönsson CEO
|
|
|
September 1, 2021
|
| Alzheimer’s disease and the neurotrophins BDNF/NGF by Prof. Maria Eriksdotter M.D., PhD
|
|
|
September 1, 2021
|
| Strategy Update on Alzheimer’s Disease & NeuroRestore
|
|
|
September 1, 2021
|
| ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021
|
|
|
July 29, 2021
|
| About AlzeCure’s origin and development – An embryo that can be something big – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)
| |
|
June 11, 2021
|
| Negative Allosteric Modulators of TrkA for the Treatment of Pain – Scientific presentation at the IASP conference on pain, June 2021
|
|
|
June 11, 2021
|
| About suffering from Alzheimer’s disease, diagnostics, care today and future needs – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)
| |
|
June 11, 2021
|
| About Alzstatin and drugs for Alzheimer’s disease – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)
| |
|
June 11, 2021
|
| ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain – Scientific presentation at the IASP conference on pain, June 2021
|
|
|
June 9, 2021
|
| Alzecure: CEO Martin Jönsson present at Redeye Growth Day
| |
|
June 7, 2021
|
| CEO presentation at the annual meeting (Swedish)
| |
|
May 20, 2021
|
| CEO Martin Jönsson after the company’s annual meeting
| |
|
May 17, 2021
|
| Update on Progress in the Painless Platform, May 11, 2021
|
|
|
May 11, 2021
|
| Company overview and goals by CEO Martin Jönsson, May 11, 2021
|
|
|
May 11, 2021
|
| Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, May 11, 2021
|
|
|
May 11, 2021
|
| ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, May 11, 2021
|
|
|
May 11, 2021
|
| TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, May 11, 2021
|
|
|
May 11, 2021
|
| Alzecure: Interview with CEO Martin Jönsson and CSO Johan Sandin (video)
| |
|
April 20, 2021
|
| Alzecure: Interview with CEOMartin Jönsson (video). (Swedish)
| |
|
March 1, 2021
|
| Interview with Martin Jönsson CEO in Aktiespararna’s analysis guide
| |
|
February 8, 2021
|
| CEO Martin Jönsson presentation, Aktiedagen Lund
| |
|
January 27, 2021
|
| Interview with Johan Sandin (CSO) in Aktiespararna’s analysis guide
| |
|
January 22, 2021
|
| Improving Quality of Life for People with Neurodegenerative Diseases – Stockholm Researchers and Health Tech Companies
|
| |
January 14, 2021
|
| Alzecure: CEO Martin Jönsson presents at Redeye Life Science Day 2020
| |
|
December 1, 2020
|
| Scientific presentation on the NeuroRestore® candidate ACD856 presented at the CTAD conference
|
|
|
November 4, 2020
|
| Scientific presentation on Alzstatin presented at the CTAD conference
|
|
|
November 4, 2020
|
| Scientific and market update with professor Henrik Zetterberg on Alzheimer’s disease, bio-markers, potential future treatments, including Alzstatin and AlzeCure
| |
|
September 30, 2020
|
| AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)
| |
|
September 8, 2020
|
| AlzeCure Science & Market update about Alzheimer’s diseas and NeuroRestore (Swedish)
| |
|
September 1, 2020
|
| Scientific presentation about ACD856, a positive modulator of neurotrophin signaling reverses scopolamine- or age-induced cognitive deficits
|
|
|
April 2, 2020
|
| Get to know AlzeCure’s CEO Martin Jönsson – Redeye interview (Swedish)
| |
|
March 19, 2020
|
| AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)
| |
|
March 16, 2020
|
| Gamma-secretase modulation results in multiple anti-amyloidogenic effects in vivo; Scientific presentation at the AAT-AD/PD conference, Italy, March 15-18, 2018
|
| |
March 15, 2018
|
| About the Alzstatin® project Disease modifying treatment of Alzheimer’s disease
| |
|
February 27, 2018
|
| Welcome to AlzeCure … Introduction film about the company (Swedish) – 1 minute
| |
|
February 27, 2018
|
| About the project NeuroRestore®, symptomatic treatment of cognitive disorders such as in Alzheimer’s disease
| |
|
February 27, 2018
|
| About Alzheimers disease
| |
|
February 27, 2018
|
